Antibiotics for SIBO: Rifaximin, Herbal Protocols, and When Each Makes Sense

Medically reviewed by Angelo Falcone, MD · Last reviewed: August 2026

The hardest part of treating small intestinal bacterial overgrowth is not choosing the antibiotic.

It is not picking between rifaximin and herbs. It is not the breath test. It is not even the diet, though that is where most people spend their energy.

The hardest part is that somewhere between a third and a half of people who clear SIBO will have it come back, and if you have not figured out why the bacteria migrated where they did not belong in the first place, you are going to be having this same conversation in nine months. I say that not to be discouraging but because I think patients deserve to know the shape of the problem before they start.

So let me walk through what antibiotics for SIBO actually do, what the evidence says about the prescription option and the herbal one, and how I think about choosing between them.

What SIBO treatment is actually trying to accomplish

Small intestinal bacterial overgrowth means bacteria that ordinarily live in your colon have set up residence higher in the small intestine, where they ferment carbohydrates before you can absorb them.

That fermentation produces gas. The gas produces the bloating, the distension that gets worse as the day goes on, the pain, the altered stools, and sometimes the fatigue and brain fog that patients find hardest to describe to a doctor.

Antimicrobial treatment, whether pharmaceutical or botanical, is aimed at reducing that bacterial population. It is a reset, not a cure. I want to be plain about that, because the word "cure" gets thrown around in this space more than the evidence supports.

One note on diagnosis before treatment, since the two are linked. Most SIBO is diagnosed by breath testing. The 2017 North American Consensus on hydrogen and methane-based breath testing set thresholds that most reputable labs now follow: a rise in hydrogen of at least 20 parts per million within 90 minutes counts as positive, and methane at or above 10 parts per million counts as methane-positive. That methane distinction matters, because methane-predominant overgrowth tends to present with constipation rather than diarrhea and responds somewhat differently to treatment. Yet a third gas, hydrogen sulfide, has been identified although it accounts for a very small percentage of cases. I mention it because it is not picked up on standard breath testing.

Rifaximin: the prescription option

Rifaximin is the antibiotic most often used for SIBO, and there is a reasonable case for why. It is essentially non-absorbed, meaning it stays in the gut and does very little systemically. That gives it a side effect profile most antibiotics would envy. In the United States it is FDA-approved for irritable bowel syndrome with diarrhea and for hepatic encephalopathy, and its use in SIBO specifically is off-label, which is common and appropriate in gastroenterology but worth knowing.

What patients are usually not told up front is the cost. Rifaximin is expensive, insurance coverage for the SIBO indication is inconsistent, and I have watched more than one patient get a prescription, get to the pharmacy counter, and simply walk away. If your physician recommends it, ask about coverage before you leave the office. That is a practical point, not a clinical one, but practical points are where treatment plans usually fall apart.

Herbal antimicrobials: what the evidence actually shows

Here is where I want to be careful, because this is the part of the conversation where integrative medicine sometimes gets ahead of its evidence.

The most cited study comparing the two is a 2014 trial published in Global Advances in Health and Medicine, which looked at 104 patients with newly diagnosed SIBO. Among those treated with herbal antimicrobials, 46 percent had a negative follow-up breath test, compared with 34 percent of those treated with rifaximin. In a crossover arm, patients who had failed rifaximin were given herbal therapy, and roughly 57 percent responded.

Those numbers get quoted a great deal in my field, usually as "herbs beat antibiotics." I do not think that is a fair reading, and I want to say why.

It was not randomized — patients chose which treatment they received, which introduces selection bias — and it was conducted at a single tertiary referral center. If a pharmaceutical company brought me a trial with those characteristics claiming superiority for their drug, I would be skeptical, and I try to hold botanical medicine to the standard I would apply to a drug.

What the study reasonably supports is a more modest claim: herbal antimicrobial protocols appear to be roughly comparable to rifaximin, and they are a legitimate option for patients who have failed rifaximin or cannot access it. That is genuinely useful. It is just not the same as "better."

The compounds involved are the ones you would expect if you have read anything in this area: berberine, oil of oregano, neem, allicin from garlic, and a handful of others, usually in combination formulas. Berberine in particular is now being studied head-to-head against rifaximin in a registered randomized trial designed to test whether it is non-inferior, which is exactly the kind of study this field needs more of. I will be interested to see where it lands.

I am not going to publish specific dosing here. Herbal antimicrobials are not benign simply because they are botanical, they interact with medications, and the right protocol depends on whether your overgrowth is hydrogen-predominant or methane-predominant. This is a supervised treatment, not a supplement-aisle project.

And since I am talking about supplements, I should disclose the obvious: our practice maintains a virtual dispensary, which means I have a financial relationship with the supplement industry, small as it is. I think you should know that when I tell you an herb might work.

How I actually decide

In practice the choice is less philosophical than people expect.

If a patient has good insurance coverage, wants the most conventionally studied option, and has no particular objection to a pharmaceutical, rifaximin is a perfectly sound first move. If a patient cannot afford it, has already failed it, has a history of poor tolerance to antibiotics, or has a strong preference for a botanical approach, herbal antimicrobials are a reasonable first move instead. Neither choice is a mistake.

What matters more than the choice, in my experience, is what surrounds it. Whether the overgrowth is methane-predominant, which changes the protocol. Whether there is an underlying motility problem, because the small intestine has a housekeeping wave that sweeps bacteria downstream between meals, and when that wave is impaired, bacteria accumulate no matter how many times you kill them off. Whether there is a structural issue, prior abdominal surgery, low stomach acid from years of acid-suppressing medication, or an untreated thyroid problem.

Treating SIBO without asking those questions is like bailing out a boat without looking for the hole. You will make progress. You will also be bailing forever.

The relapse problem nobody wants to talk about

I spent 25 years in emergency medicine before I moved into integrative practice, and one habit that stuck with me is asking what brings people back. In the emergency department, the return visit tells you what the first visit missed or simply that the condition progressed or changed as often happens.

SIBO has a high return visit rate, especially for the methane predominant type now named Intestinal Methanogen Overgrowth. Reported relapse rates vary widely depending on the population studied and how long people are followed, but recurrence is common enough that any honest treatment conversation has to include it. The patients who do best over the long run, in my practice, are not the ones who found the perfect antimicrobial. They are the ones who addressed motility, gave the meal-spacing question serious attention, worked on the stress physiology that suppresses gut motor function, and treated the underlying condition that set the stage.

That is slower and less satisfying than a two-week course of anything. It is also, I think, where the actual medicine is.

If you want to go deeper on the surrounding pieces, we have written about how often SIBO recurs and why, about why SIBO treatment requires a particular kind of attention, and about what the microbiome actually is, which is useful background for all of this. Our approach to SIBO testing and treatment lays out how we work through it.

The short version

Antibiotics for SIBO work, in the sense that they reduce bacterial populations and relieve symptoms for a meaningful number of people. Rifaximin has the better evidence base. Herbal protocols have a smaller but real evidence base and appear to be roughly comparable, particularly for people who have already failed rifaximin. Anyone who tells you one is definitively superior is telling you something the literature does not currently support.

The more important question is not which antimicrobial. It is why the bacteria were there to begin with, and what has to change so they do not come back.

If you have been through a round of treatment for SIBO and the symptoms have returned, or you are trying to decide between antibiotics and a botanical protocol and want someone to think it through with you, you can schedule a free consultation with us at Dignity Integrative. We serve Rockville, Bethesda, Germantown, Gaithersburg, Olney and the surrounding area.

This article is for general information and is not a substitute for individual medical advice. Please talk with your own physician about your particular situation.